1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
View Patent ↗The present invention relates to 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives of formula (I), wherein R 1 is as defined in the description, their preparation and their use as pharmaceutically active compounds.
1. A compound of formula (I)
wherein
R 1 represents hydrogen or fluoro;
or a salt thereof.
2. The compound according to claim 1 , wherein
R 1 represents hydrogen; or a salt thereof.
3. The compound according to claim 1 , wherein
R 1 represents fluoro; or a salt thereof.
4. The compound according to claim 1 , wherein the compound is: (5R)—N5-(1-(p-tolyl)cyclopropyl)-(6R)—N6-(4-(pyrrolidino)butyl)-(4S,7R)-[4,7-ethylene-spiro[2.4]heptane]-5,6-dicarboxamide; or a salt thereof.
5. A medicament comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising, as active principle, a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
7. A method of treating a disease comprising administering to a subject in need thereof a compound according to claim 1 , wherein the disease is inflammatory diseases, obstructive airway diseases, allergic conditions, HIV-mediated retroviral infections, cardiovascular disorders, neurological disorders, pain, or amyloid-mediated disorders.
8. A method of treating a disease comprising administering to a subject in need thereof a pharmaceutical composition according to claim 6 , wherein the disease is inflammatory diseases, obstructive airway diseases, allergic conditions, HIV-mediated retroviral infections, cardiovascular disorders, neurological disorders, pain, or amyloid-mediated disorders.
9. A method of modulating an immune response in a subject comprising administering to the subject in need thereof a compound according to claim 1 .
10. A method of modulating an immune response in a subject comprising administering to the subject in need thereof the pharmaceutical composition according to claim 6 .
11. A method of treating a disease comprising administering to a subject in need thereof the compound according to claim 1 , wherein the disease is neuroinflammation.
12. A method of treating a disease comprising administering to a subject in need thereof the pharmaceutical composition according to claim 6 , wherein the disease is neuroinflammation.
13. A method of treating a disease comprising administering to a subject in need thereof the compound according to claim 1 , wherein the disease is a prion-mediated disease.
14. A method of treating a disease comprising administering to a subject in need thereof the pharmaceutical composition according to claim 6 , wherein the disease is a prion-mediated disease.
15. A method of treating a disease comprising administering to a subject in need thereof the compound according to claim 1 , wherein the disease is rheumatoid arthritis, acute lung injury, asthma, cystic fibrosis, inflammatory bowel disease, keratoconjunctivitis sicca, HIV-mediated retroviral infections, cardiovascular disorders, atopic dermatitis, pulmonary fibrosis or Alzheimer's disease.
16. A method of treating a disease comprising administering to a subject in need thereof the pharmaceutical composition according to claim 6 , wherein the disease is rheumatoid arthritis, acute lung injury, asthma, cystic fibrosis, inflammatory bowel disease, keratoconjunctivitis sicca, HIV-mediated retroviral infections, cardiovascular disorders, atopic dermatitis, pulmonary fibrosis or Alzheimer's disease.